SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: Arthur Radley who wrote (14875)12/22/2004 12:36:20 PM
From: Arthur Radley  Read Replies (1) | Respond to of 52153
 
WE have recently had some discussion about DSCO and the potential of this stock, so I'm wondering if anyone has an opinion on NKTR. The reason I ask is that with their recent news on the EYET deal they have picked up a little steam..making my "small" holding perk-up a tad. However, IMO the real kicker for this stock will be the forthcoming inhalable form of insulin...Exubera. My concern is that any drug dealing with the lungs has the potential for a host of side-effects. Any opinions out there?